(S)-(2-cyclohexyl-1-formylethyl)carbamic acid,1,1-dimethylethyl ester | 103127-55-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-(2-cyclohexyl-1-formylethyl)carbamic acid,1,1-dimethylethyl ester
• 英文别名: 2(S)-t-butyloxycarbonylamino-3-cyclohexylpropanal；3-cyclohexyl-2-(tert-butoxycarbonylamino)propionaldehyde；2-t-butoxycarbonylamino-3-cyclohexylpropyl aldehyde；(2-cyclohexyl-1-formylethyl)-carbamic acid tert-butyl ester；tert-Butyl (1-cyclohexyl-3-oxopropan-2-yl)carbamate；tert-butyl N-(1-cyclohexyl-3-oxopropan-2-yl)carbamate
• CAS: 103127-55-5
• 化学式: C₁₄H₂₅NO₃
• 分子量: 255.357
• InChiKey: WRSGJTAPAYTZOO-UHFFFAOYSA-N

物化性质

• 沸点：
  363.0±25.0 °C(Predicted)
• 密度：
  1.008±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-(2-cyclohexyl-1-formylethyl)carbamic acid,1,1-dimethylethyl ester 在 N-甲基吗啉 、 盐酸 、 lithium hydroxide 、 双氧水 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 3-羟基-1,2,3-苯并三嗪-4(3H)-酮 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 {(S)-2-[(1R,2S,5S)-2-(2-Carbamoyl-1-cyclohexylmethyl-2-hydroxy-ethylcarbamoyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxo-ethyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor:  A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection

  摘要：

  Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-alpha or polyethylene glycol (PEG)-interferon-alpha alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.

  DOI：

  10.1021/jm060325b
• 作为产物：
  描述：

  2-t-butoxycarbonylamino-3-cyclohexylpropionic acid methyl ester 在 二异丁基氢化铝 作用下， 以 甲醇 、 正己烷 、 甲苯 为溶剂， 生成 (S)-(2-cyclohexyl-1-formylethyl)carbamic acid,1,1-dimethylethyl ester
  参考文献：
  名称：

  Amino acid derivatives which have renin inhibiting activity

  摘要：

  公式##STR1##的化合物，其中A、R.sup.1、R.sup.2、R.sup.3和R.sup.4的含义如权利要求1所述，以光学纯对映异构体、对映异构体混合物、对映异构体外消旋混合物或对映异构体外消旋混合物的形式，以及它们的药用盐，能够抑制天然酶肾素的活性，因此可以以药物制剂的形式用于控制或预防高血压和心脏衰竭。

  公开号：

  US05140011A1

文献信息

• [EN] TRNA SYNTHETASE INHIBITORS<br/>[FR] INHIBITEURS D'ARNT SYNTHÉTASE
  申请人：HARVARD COLLEGE

  公开号：WO2019140265A1

  公开（公告）日：2019-07-18

  Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

  本文披露了一种抑制tRNA合成酶的二级胺化合物。本发明的化合物在抑制革兰氏阴性细菌中的tRNA合成酶方面是有用的，并且在杀灭革兰氏阴性细菌方面也是有用的。本发明的二级胺化合物还在结核病的治疗中是有用的。
• N-morpholino derivatives and their use as anti-hypertensive agents
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US05055466A1

  公开（公告）日：1991-10-08

  Compounds of the formula ##STR1## are disclosed. These compounds are inhibitors of renin and therefore useful as cardiovascular agents.

  公开了式##STR1##的化合物。这些化合物是肾素抑制剂，因此可用作心血管药物。
• N-heterocyclic alcohol renin inhibitors
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04885292A1

  公开（公告）日：1989-12-05

  Compounds of the formula ##STR1## are disclosed wherein R.sub.1 is N-heterocyclic moiety. These compounds intervene in the conversion of angiotensin to angiotensin II by inhibiting renin and thus are useful as antihypertensive agents.

  公式为##STR1##的化合物被披露，其中R.sub.1是N-杂环基团。这些化合物通过抑制肾素干预将血管紧张素转化为血管紧张素II，因此可用作降压药物。
• Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists
  申请人：Saito Daisuke Roland

  公开号：US20090062332A1

  公开（公告）日：2009-03-05

  The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

  该发明提供了新颖的8-azabicyclo[3.2.1]辛烷化合物，化学式为(I)：其中变量在规范中有定义，或其药用盐，这些化合物是μ阿片受体拮抗剂。该发明还提供了包含这些化合物的药物组合物，使用这些化合物治疗与μ阿片受体活性相关的疾病的方法，以及用于制备这些化合物的过程和中间体。
• Method for the production of aldehydes
  申请人：Hoffmann-La Roche Inc.

  公开号：US05321166A1

  公开（公告）日：1994-06-14

  A process for the manufacture of aldehydes by the catalytic reduction of carboxylic acid halides with hydrogen in the presence of an alkylene oxide.

  一种通过在存在烷基氧化物的条件下，将羧酸卤化物与氢气进行催化还原制备醛的工艺。